Multiple sclerosis (MS) is a disease in which your immune system mistakenly attacks the protective coating around nerves in the brain and spinal cord. This coating, called myelin, works like insulation on electrical wiring, allowing nerve signals to travel quickly and efficiently. When it’s damaged, signals slow down, get distorted, or stop entirely, producing symptoms that range from blurred vision to difficulty walking. About 85 to 90% of people with MS start with a relapsing-remitting pattern, where symptoms flare up and then partially or fully recover, while 10 to 15% experience a steady decline from the beginning.
How the Immune System Turns on Itself
MS begins when certain white blood cells become “autoreactive,” meaning they mistake proteins in your own nervous system for foreign threats. The key players are a type of immune cell called CD4+ T-cells, which coordinate the attack, and CD8+ T-cells, which actually outnumber CD4+ cells inside MS lesions and can directly kill nerve-insulating cells. B-cells contribute by producing antibodies that tag myelin for destruction. Macrophages then arrive and physically engulf the debris, essentially eating the damaged myelin and the cells that produce it.
These immune cells don’t just release a single weapon. They flood the area with toxic compounds, including enzymes that break down proteins, inflammatory signaling molecules, and nitric oxide. The cells that manufacture myelin, called oligodendrocytes, are hit from multiple angles: antibodies coat them for destruction, the complement system (a chemical cascade that punches holes in cell membranes) breaks them apart, and macrophages ingest whatever remains. It’s a coordinated assault rather than a single malfunction.
Breaking Through the Brain’s Defenses
Your brain has a security system called the blood-brain barrier, a tightly sealed layer of cells lining the blood vessels that normally prevents immune cells and harmful substances from entering the central nervous system. In MS, this barrier breaks down. Inflammatory signals cause the tight junctions between these barrier cells to loosen, creating gaps that activated immune cells can squeeze through. Once inside, they encounter nerve tissue and begin the attack cycle.
This breach is why relapses happen. During a flare, a fresh wave of immune cells pushes through the damaged barrier, creating new areas of inflammation and myelin loss. On MRI scans, these active breaches show up as bright spots when contrast dye is injected, because the dye leaks through the same gaps the immune cells used.
Myelin Loss vs. Permanent Nerve Damage
Not all damage in MS is equal. Early on, the body can often repair stripped myelin to some degree, which is why many people recover function after a relapse. But there’s a tipping point. Research tracking nerve fiber thickness over time found that people with more severe demyelination lost nerve fibers at a significantly faster rate (about 0.6% more per year) compared to people with mild demyelination, where no measurable difference in nerve loss occurred. In other words, when myelin damage stays mild, the underlying nerves tend to hold up. When demyelination is extensive or repeated, the bare nerve fibers themselves start to degenerate, and that damage is permanent.
This is the critical distinction in MS. Myelin can be repaired. Nerve fibers, once lost, cannot. The goal of treatment is to stop immune attacks before they cross that threshold from repairable insulation damage to irreversible nerve death.
Why the Disease Keeps Progressing
Many people with MS eventually notice a slow worsening that happens between or even without obvious relapses. This “smoldering” process involves at least two overlapping mechanisms. First, chronic active lesions (sometimes called rim lesions) harbor immune cells at their edges that keep slowly expanding the damage outward, even when no new relapses are occurring. Second, inflammation along the brain’s surface strips myelin from the outer layers of the cortex, which standard MRI scans can miss entirely.
On top of the inflammatory damage, there’s a degenerative component. Nerve fibers stripped of myelin have to work harder to conduct signals, creating an energy crisis at the cellular level. Their mitochondria, the tiny power generators inside each cell, can’t keep up with demand. Support cells that normally mop up excess glutamate (a chemical that becomes toxic at high levels) lose their ability to do so, leading to further cell death. Aging compounds the problem: people with MS who have already lost nerve reserve from earlier attacks experience normal age-related brain changes more severely and sooner than they otherwise would. Vascular health conditions like high blood pressure or diabetes can accelerate this process further.
What Triggers MS in the First Place
The Epstein-Barr virus (EBV), which causes mono and infects more than 95% of humans, is now considered a necessary trigger for MS. In a landmark military study tracking 801 MS cases, only a single person developed MS without prior EBV infection. All other 35 initially EBV-negative individuals became infected with the virus before their MS appeared. EBV infection is necessary, but not sufficient on its own. Most people infected with EBV never develop MS.
The mechanism appears to be molecular mimicry. A protein the virus produces (called EBNA1) contains stretches of amino acids that closely resemble proteins found on the surface of brain cells. The immune system, primed to fight the virus, produces antibodies that cross-react with these brain proteins. Research comparing 650 MS patients with 661 matched controls found that people who carry a specific genetic risk marker and have elevated antibodies against both the viral protein and its brain look-alike face roughly 9 to 10 times the risk of developing MS compared to people without those factors. This helps explain why MS requires a combination of genetic susceptibility and an environmental trigger.
How MS Is Diagnosed
Diagnosis relies on showing that damage has occurred in at least two separate areas of the central nervous system (dissemination in space) at two different points in time (dissemination in time). This framework, known as the McDonald criteria, uses a combination of clinical symptoms, MRI findings, and sometimes spinal fluid analysis. MRI can reveal lesions in the brain, spinal cord, and optic nerves. If a spinal tap shows specific immune markers called oligoclonal bands (antibodies produced within the central nervous system), that finding can now substitute for proof of dissemination in time, potentially speeding up diagnosis.
The emphasis on “no better explanation” is central. Doctors must rule out conditions that mimic MS, including certain infections, vitamin deficiencies, and other autoimmune diseases, before confirming the diagnosis.
Common Early Symptoms
MS can affect virtually any function controlled by the brain and spinal cord, but certain patterns appear more often. Optic neuritis, inflammation of the nerve connecting the eye to the brain, is one of the most common first symptoms. It typically causes pain with eye movement and blurred or lost vision in one eye. The optic nerve is vulnerable because, like all central nervous system tissue, its myelin is a target for the misguided immune response.
Other frequent early symptoms include numbness or tingling in the limbs, muscle weakness or stiffness, balance problems, and overwhelming fatigue that’s disproportionate to physical activity. Symptoms depend entirely on where in the brain or spinal cord the immune attack lands, which is why MS looks so different from person to person.
How Treatments Interrupt the Cycle
Current MS treatments fall into several broad categories based on how they disrupt the immune attack. Some therapies trap immune cells in the lymph nodes so they never reach the brain. Others selectively deplete B-cells, removing the cells responsible for producing myelin-targeting antibodies. A third approach, immune reconstitution therapy, works by temporarily wiping out portions of the immune system and allowing it to rebuild. The rebuilt immune system often functions normally for years after treatment, suggesting the “reset” clears out the autoreactive cells that were driving the disease.
These treatments can dramatically reduce relapses and new lesion formation, but they’re most effective against the inflammatory component of MS. The smoldering, degenerative processes described above are harder to reach with current therapies, which is why early and aggressive treatment, before significant nerve loss accumulates, leads to better long-term outcomes. Life expectancy for people with MS has improved substantially with modern treatments and now approaches that of the general population, whereas older studies had estimated a gap of up to 10 years.